02/23/2019 The Ultra-Rapid Insulin BioChaperone® Lispro bolused by insulin pump shows favourable pharmacodynamics and pharmacokinetics vs. faster Aspart and insulin Aspart, Dr. Grégory Meiffren, February 23, 2019, ATTD, Berlin (Germany)
02/22/2019 “BioChaperone® Glucagon, A Stable Ready-To-Use Liquid Glucagon Formulation Enabled By Biochaperone Technology, Is Well Tolerated And Quickly Restores Euglycemia After Insulin-Induced Hypoglycemia” (E-Poster Discussion 05), presented by Mr. Aymeric Ranson, February 22, 2019, ATTD, Berlin (Germany) Icon check
02/21/2019 “BioChaperone® Combo, A Co-Formulation Of Lispro And Glargine, Improves Postprandial Glucose Control Compared To Lispromix25 Or Lispro And Glargine Injections In Type 2 Diabetes Subjects” (EPO2 E-Poster Viewing), presented by Dr. Grégory Meiffren, February 21, 2019, ATTD, Berlin (Germany) Icon check
02/12/2019 Adocia to Present New Clinical Data on BioChaperone® Technology at ATTD 2019 Icon check
02/08/2019 Number of shares and voting rights of ADOCIA as of January 31, 2019 Icon check
01/17/2019 BioChaperone Lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: A randomized euglycemic clamp study. Diabetes Obes Metab., 2019;21(4):1066-1070. Icon check
01/16/2019 Adocia confirms its financial calendar for 2019 Icon check
01/10/2019 Number of shares and voting rights of ADOCIA as of December 31, 2018 Icon check
01/03/2019 PR: Adocia Announces a Clinical Trial Evaluating BioChaperone® Lispro and Other Rapid-Acting Insulin Analogs Using iLetTM Bionic Pancreas Icon check
12/20/2018 Adocia announces its financial calendar for 2019 Icon check
12/06/2018 Number of shares and voting rights of ADOCIA as of November 30, 2018 Icon check
11/25/2018 Andersen G, Meiffren G, Lamers D, DeVries JH, Ranson A, Seroussi C, Alluis B, Gaudier M, Soula O, Heise T.
“Ultra-rapid BioChaperone® Lispro improves postprandial blood glucose excursions vs insulin lispro in a 14-day crossover treatment study in people with type 1 diabetes.”
Diabetes Obes Metab., 2018;20(11):2627-2632. Icon check
11/07/2018 Number of shares and voting rights of ADOCIA as of October 31, 2018 Icon check
10/23/2018 Adocia Announces Third Quarter 2018 Financial Results Icon check
10/11/2018 Adocia informs about a civil action filed by Eli Lilly Icon check
10/05/2018 Adocia to hold an ordinary shareholders’ meeting on November 9, 2018 in Lyon Icon check
10/05/2018 The ultra-rapid insulin BioChaperone® Lispro shows favourable pharmacodynamics and pharmacokinetics compared to faster insulin aspart and insulin aspart in insulin pumps, Dr. Grégory Meiffren, 54th Annual Meeting of the European Association for the Study of Diabetes, 1-5 October 2018, Berlin (Germany)
10/05/2018 BioChaperone® Lispro, an Ultra-Rapid Insulin Lispro formulation improves post-prandial blood glucose control in a 14-day multiple daily insulin injection study in Subjects with T1DM, Dr. Grégory Meiffren, February 14-17, 2018, ATTD, Vienna (Austria)
10/05/2018 “BioChaperone® technology enables the development of pramlintide-prandial insulin combinations” (Poster 811), presented by Dr. Remi Soula, 54th Annual Meeting of the European Association for the Study of Diabetes, 1-5 October 2018, Berlin (Germany)
10/04/2018 Number of shares and voting rights of ADOCIA as of September 30, 2018 Icon check
10/01/2018 “BioChaperone® 222, the new excipient enabling the ultra-rapid BioChaperone® Lispro formulation, is completely absorbed and rapidly excreted after subcutaneous injection” (Poster 816), presented by Dr. Olivier Soula, 54th Annual Meeting of the European Association for the Study of Diabetes, 1-5 October 2018, Berlin (Germany)
10/01/2018 The ultra-rapid insulin BioChaperone® Lispro shows favourable pharmacodynamics and pharmacokinetics compared to faster insulin aspart and insulin aspart in insulin pumps, Dr. Grégory Meiffren, 54th Annual Meeting of the European Association for the Study of Diabetes, 1-5 October 2018, Berlin (Germany)
10/01/2018 “BioChaperone® 222, the new excipient enabling the ultra-rapid BioChaperone® Lispro formulation, is completely absorbed and rapidly excreted after subcutaneous injection” (Poster 816), presented by Dr. Olivier Soula, 54th Annual Meeting of the European Association for the Study of Diabetes, 1-5 October 2018, Berlin (Germany)
10/01/2018 “Better Postprandial Glucose (PPG) Control with BioChaperone® Combo (BC Combo) than with Lispro Mix25 (LMx) or separate Glargine & Lispro (G+L) Administration in Subjects with Type 2 Diabetes (T2DM)” (Poster 1001), presented by Dr. Tim Heise, 78th Scientific Sessions of the American Diabetes Association, 22-26 June 2018, Orlando, FL (USA)
09/26/2018 Adocia to Present Five Abstracts at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD) Icon check
09/20/2018 “Pooled Analysis of Clinical Trials Investigating the Pharmacokinetics (PK) of Ultra-Rapid Insulin BioChaperone® Lispro (BCLIS) versus Lispro (LIS) in Subjects with Type 1 (T1D) and Type 2 (T2D) Diabetes” (Poster 998), presented by Dr. Tim Heise, 78th Scientific Sessions of the American Diabetes Association, 22-26 June 2018, Orlando, FL (USA)
09/06/2018 Number of shares and voting rights of ADOCIA as of August 31, 2018 Icon check
09/05/2018 Adocia announces positive topline results for the first clinical study of BioChaperone® Pramlintide Insulin in people with type 1 diabetes Icon check
08/30/2018 Adocia Announces Update to Second Arbitration Against Eli Lilly & Company Icon check
08/21/2018 Number of shares and voting rights of ADOCIA as of July 31, 2018 Icon check
08/08/2018 American Arbitration Association Panel Finds In Favor Of Adocia In First Phase Of Arbitration Against Eli Lilly Icon check
07/18/2018 Adocia Presents First Half 2018 Financial Results Icon check
07/12/2018 Ultra-rapid BioChaperone® Lispro improves postprandial blood glucose excursions vs insulin lispro in a 14-day crossover treatment study in people with type 1 diabetes. Diabetes Obes Metab., 2018;20(11):2627-2632. Icon check
07/04/2018 Number of shares and voting rights of ADOCIA as of June 30, 2018 Icon check
06/26/2018 BioChaperone® Glucagon, a stable ready-to-use liquid glucagon formulation, is well tolerated and quickly restores euglycemia after insulin-induced hypoglycemia, by Dr. Grégory Meiffren, 78th Scientific Sessions of the American Diabetes Association, 22-26 June 2018, Orlando, FL (USA)
06/26/2018 BioChaperone® Technology Enables the Development of Pramlintide-Prandial Insulin Combinations, Dr. Grégory Meiffren, 78th Scientific Sessions of the American Diabetes Association, 22-26 June 2018, Orlando, FL (USA)
06/25/2018 BioChaperone® Technology Enables the Development of Pramlintide-Prandial Insulin Combinations, Dr. Grégory Meiffren, 78th Scientific Sessions of the American Diabetes Association, 22-26 June 2018, Orlando, FL (USA)
06/22/2018 “Pooled Analysis of Clinical Trials Investigating the Pharmacokinetics (PK) of Ultra-Rapid Insulin BioChaperone® Lispro (BCLIS) versus Lispro (LIS) in Subjects with Type 1 (T1D) and Type 2 (T2D) Diabetes” (Poster 998), presented by Dr. Tim Heise, 78th Scientific Sessions of the American Diabetes Association, 22-26 June 2018, Orlando, FL (USA)
06/22/2018 “Better Postprandial Glucose (PPG) Control with BioChaperone® Combo (BC Combo) than with Lispro Mix25 (LMx) or separate Glargine & Lispro (G+L) Administration in Subjects with Type 2 Diabetes (T2DM)” (Poster 1001), presented by Dr. Tim Heise, 78th Scientific Sessions of the American Diabetes Association, 22-26 June 2018, Orlando, FL (USA)
06/22/2018 BioChaperone® Glucagon, a stable ready-to-use liquid glucagon formulation, is well tolerated and quickly restores euglycemia after insulin-induced hypoglycemia, by Dr. Grégory Meiffren, 78th Scientific Sessions of the American Diabetes Association, 22-26 June 2018, Orlando, FL (USA)
06/22/2018 “The Ultra-Rapid Insulin (URI) BioChaperone® Lispro (BCLIS) shows Favorable Pharmacodynamics (PD) and Pharmacokinetics (PK) vs Faster Aspart (FIA) and Insulin Aspart (ASP) in Insulin Pumps (CSII)” (Poster 1035), presented by Dr. Bruce W. Bode, 78th Scientific Sessions of the American Diabetes Association, 22-26 June 2018, Orlando, FL (USA)
06/22/2018 “BioChaperone® Lispro, une formulation ultra-rapide d’insuline lispro, améliore le contrôle glycémique post-prandial de sujets diabétiques de type 1 traités par de multiples injections quotidiennes d’insuline pendant 14 jours.” (Abstract CAD-19), presented by Dr. Grégory Meiffren, 2018, Société Francophone du Diabète (France)
06/22/2018 “Ultra-rapid BioChaperone® Lispro ameliorates postprandial blood glucose (PPG) control compared to Humalog in subjects with type 1 diabetes mellitus” (Poster PI005), presented by Dr G. Anderson, American Society for Clinical Pharmacology & Therapeutics (ASCPT)
06/15/2018 Ultra-Rapid BioChaperone® Lispro ameliorates postprandial blood glucose control compared with Humalog(R) in subjects with type 1 diabetes mellitus, Dr. Grit Anderen, 76th Scientific Sessions American Diabetes Association 10-14 June 2016, New Orleans, LO (USA)
06/14/2018 Adocia to Present Six Abstracts at the American Diabetes Association® 78th Scientific Sessions Icon check
06/11/2018 BioChaperone® Combo (BC Combo) improves postprandial glycemia vs. Humalog® Mix 75/25™ (HMx) in people with type 1 diabetes mellitus (T1DM, Dr. Steven V. Edelman, 76th Scientific Sessions American Diabetes Association 11-13 June 2016, New Orleans, LO (USA)
06/08/2018 Number of shares and voting rights of ADOCIA as of May, 31 2018 Icon check
06/05/2018 Adocia to Participate in the Jefferies 2018 Global Healthcare Conference Icon check
06/01/2018 Adocia and Tonghua Dongbao Announce Global Supply Agreements for Insulin Lispro and Insulin Glargine Icon check
05/07/2018 Number of shares and voting rights of ADOCIA as of April, 30 2018 Icon check
05/02/2018 Adocia to hold conference call in regard to the Strategic Alliance for BioChaperone® Combo and BioChaperone® Lispro in China with Tonghua Dongbao Icon check
04/26/2018 Adocia and Tonghua Dongbao Announce a Strategic Alliance for BioChaperone®Combo and BioChaperone® Lispro in China. Icon check
04/19/2018 Adocia announces the release of its Reference Document for the year 2017 Icon check
04/16/2018 Number of shares and voting rights of ADOCIA as of March, 31 2018 Icon check
04/16/2018 Adocia initiates First-in-Human Clinical Study of BioChaperone® Pramlintide Insulin in people with type 1 diabetes Icon check
04/16/2018 Adocia announces first quarter 2018 financial results: Cash position and revenue Icon check
04/09/2018 Adocia to hold its annual shareholders’ meeting on May 17, 2018 in Lyon Icon check
03/19/2018 ADOCIA announced its financial results for 2017 and its perspectives for 2018 Icon check
03/06/2018 Number of shares and voting rights of ADOCIA as of February 28, 2018 Icon check
02/17/2018 BioChaperone® Lispro, an Ultra-Rapid Insulin Lispro formulation improves post-prandial blood glucose control in a 14-day multiple daily insulin injection study in subjects with T2DM, Dr. Grégory Meiffren, February 14-17, 2018, ATTD, Vienna (Austria)
Join our mailing list. Subscribe